Shopping Cart 0
Cart Subtotal
AED 0

Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 19708

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 33012

Details

According to a new report published by Allied Market Research, titled,"Oncology/Cancer drugs market by Treatment Type: Global Opportunity Analysis and Industry Forecast, 2018-2025"the market was valued at USD 97,401 million in 2017, and is projected to reach USD 176,509 million by 2025, growing at a CAGR of 7.6% from 2018 to 2025.

 

Cancer is caused when the cells present in the body grow at an uncontrolled rate leading to the formation of a tumor. Cancer has different stages based on its progression. Metastasis is the final stage of the disease, which is marked by the invasion of tumor into others parts of body. The management of cancer in patients requires the use of different drugs such as hormonal therapy, immunotherapy, targeted therapy, and others.

 

The key drivers of the global oncology/cancer drugs market are surge in geriatric population and rise in collaborations & partnerships to facilitate drug development. In addition, surge in prevalence of cancer and increase in healthcare expenditure have significantly contributed toward the growth of this market. Increase in number of pipeline drugs along with high potential of emerging economies are further expected to provide lucrative opportunities for market expansion. However, adverse effects related to cancer drugs impede the market growth.

 

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

 

Regionally, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

 

Key Findings of the Oncology/Cancer drugs market:

North America occupied nearly half share of the global oncology/cancer drugs market in 2017.

The immunotherapy segment is anticipated to grow with the highest CAGR throughout the forecast period.

The breast cancer segment accounted for less than one-seventh share of the market in 2017.

Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

North America was the leading revenue contributor to the global market in 2017, garnering nearly 47.65% of the total market share, owing to high adoption rate of cancer drugs. However, Asia-Pacific is expected to grow at the highest CAGR of 9.5% from 2018 to 2025, owing to increase in disposable income; surge in research, development, & innovation activities; and rise in awareness related to different cancers.

The report provides an extensive competitive analysis and profiles of the key market players such as Amgen Inc., Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi.

 

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

 

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

READ MORE

Table Of Content

Scope

CHAPTER 1: INTRODUCTION

 

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

 

1.3.1. List of key players profiled in the report

 

1.4. Research methodology

 

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

 

CHAPTER 2: EXECUTIVE SUMMARY

 

2.1. Key findings of the study

2.2. CXO perspective

 

CHAPTER 3: MARKET OVERVIEW

 

3.1. Market definition and scope

3.2. Key findings

 

3.2.1. Top investment pockets

3.2.2. Top winning strategies, 2017

 

3.3. Top player positioning, 2017

3.4. Porters five forces analysis

3.5. Clinical trials

3.6. Patent analysis (2015-2018)

 

3.6.1. Patent analysis, world

3.6.2. Patent analysis, by year

 

3.7. Market dynamics

 

3.7.1. Drivers

 

3.7.1.1. Rise in incidence of cancer across the globe

3.7.1.2. Surge in global geriatric population

3.7.1.3. Increase in government expenditures on healthcare

 

3.7.2. Restraints

 

3.7.2.1. Adverse effects associated with the use of cancer drugs

 

3.7.3. Opportunities

 

3.7.3.1. Untapped emerging economies

3.7.3.2. Increase in number of pipeline drugs

 

3.7.4. Impact Analyses

 

CHAPTER 4: ONCOLOGY/ CANCER DRUGS MARKET, BY DRUG CLASS TYPE

 

4.1. Overview

 

4.1.1. Market size and forecast

 

4.2. Chemotherapy

 

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market analysis, by country

 

4.3. Targeted Therapy

 

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market analysis, by country

 

4.4. Immunotherapy (Biologic Therapy)

 

4.4.1. Key market trends, growth factors, and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market analysis, by country

 

4.5. Hormonal Therapy

 

4.5.1. Key market trends, growth factors, and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market analysis, by country

 

CHAPTER 5: ONCOLOGY/ CANCER DRUGS MARKET, BY INDICATION

 

5.1. Overview

 

5.1.1. Market size and forecast

 

5.2. Lung Cancer

 

5.2.1. Market size and forecast, by region

5.2.2. Market share analysis, by country

 

5.3. Stomach Cancer

 

5.3.1. Market size and forecast, by region

5.3.2. Market analysis, by country

 

5.4. Colorectal Cancer

 

5.4.1. Market size and forecast, by region

5.4.2. Market share analysis, by country

 

5.5. Breast Cancer

 

5.5.1. Market size and forecast, by region

5.5.2. Market share analysis, by country

 

5.6. Prostate Cancer

 

5.6.1. Market size and forecast, by region

5.6.2. Market share analysis, by country

 

5.7. Liver Cancer

 

5.7.1. Market size and forecast, by region

5.7.2. Market share analysis, by country

 

5.8. Esophagus Cancer

 

5.8.1. Market size and forecast, by region

5.8.2. Market share analysis, by country

 

5.9. Cervical Cancer

 

5.9.1. Market size and forecast, by region

5.9.2. Market share analysis, by country

 

5.10. Kidney Cancer

 

5.10.1. Market size and forecast, by region

5.10.2. Market share analysis, by country

 

5.11. Bladder Cancer

 

5.11.1. Market size and forecast, by region

5.11.2. Market share analysis, by country

 

5.12. Other Cancers

 

5.12.1. Market size and forecast, by region

5.12.2. Market share analysis, by country

 

CHAPTER 6: ONCOLOGY/ CANCER DRUGS MARKET, BY REGION

 

6.1. Overview

 

6.1.1. Market size and forecast

 

6.2. North America

 

6.2.1. Key market trends, growth factors, and opportunities

6.2.2. Market size and forecast, by country

 

6.2.2.1. U.S.

 

6.2.2.1.1. U.S. oncology/cancer drugs market, by drug class type

6.2.2.1.2. U.S. oncology/cancer drugs market, by indication

 

6.2.2.2. Canada

 

6.2.2.2.1. Canada oncology/cancer drugs market, by drug class type

6.2.2.2.2. Canada oncology/cancer drugs market, by indication

 

6.2.2.3. Mexico

 

6.2.2.3.1. Mexico oncology/cancer drugs market, by drug class type

6.2.2.3.2. Mexico oncology/cancer drugs market, by indication

 

6.2.3. Market size and forecast, by drug class type

6.2.4. Market size and forecast, by indication

 

6.3. Europe

 

6.3.1. Key market trends, growth factors, and opportunities

6.3.2. Market size and forecast, by country

 

6.3.2.1. Germany

 

6.3.2.1.1. Germany oncology/cancer drugs market, by drug class type

6.3.2.1.2. Germany oncology/cancer drugs market, by indication

 

6.3.2.2. France

 

6.3.2.2.1. France oncology/cancer drugs market, by drug class type

6.3.2.2.2. France oncology/cancer drugs market, by indication

 

6.3.2.3. UK

 

6.3.2.3.1. UK oncology/cancer drugs market, by drug class type

6.3.2.3.2. UK oncology/cancer drugs market, by indication

 

6.3.2.4. Italy

 

6.3.2.4.1. Italy oncology/cancer drugs market, by drug class type

6.3.2.4.2. Italy oncology/cancer drugs market, by indication

 

6.3.2.5. Spain

 

6.3.2.5.1. Spain oncology/cancer drugs market, by drug class type

6.3.2.5.2. Spain oncology/cancer drugs market, by indication

 

6.3.2.6. Rest of Europe

 

6.3.2.6.1. Rest of Europe oncology/cancer drugs market, by drug class type

6.3.2.6.2. Rest of Europe oncology/cancer drugs market, by indication

 

6.3.3. Market size and forecast, by drug class type

6.3.4. Market size and forecast, by indication

 

6.4. Asia-Pacific

 

6.4.1. Key market trends, growth factors, and opportunities

6.4.2. Market size and forecast, by country

 

6.4.2.1. Japan

 

6.4.2.1.1. Japan oncology/cancer drugs market, by drug class type

6.4.2.1.2. Japan oncology/cancer drugs market, by indication

 

6.4.2.2. China

 

6.4.2.2.1. China oncology/cancer drugs market, by drug class type

6.4.2.2.2. China oncology/cancer drugs market, by indication

 

6.4.2.3. Australia

 

6.4.2.3.1. Australia oncology/cancer drugs market, by drug class type

6.4.2.3.2. Australia oncology/cancer drugs market, by indication

 

6.4.2.4. India

 

6.4.2.4.1. India oncology/cancer drugs market, by drug class type

6.4.2.4.2. India oncology/cancer drugs market, by indication

 

6.4.2.5. South Korea

 

6.4.2.5.1. South Korea oncology/cancer drugs market, by drug class type

6.4.2.5.2. South Korea oncology/cancer drugs market, by indication

 

6.4.2.6. Rest of Asia-Pacific

 

6.4.2.6.1. Rest of Asia-Pacific oncology/cancer drugs market, by drug class type

6.4.2.6.2. Rest of Asia-Pacific oncology/cancer drugs market, by indication

 

6.4.3. Market size and forecast, by drug class type

6.4.4. Market size and forecast, by indication

 

6.5. LAMEA

 

6.5.1. Key market trends, growth factors, and opportunities

6.5.2. Market size and forecast, by country

 

6.5.2.1. Brazil

 

6.5.2.1.1. Brazil oncology/cancer drugs market, by drug class type

6.5.2.1.2. Brazil oncology/cancer drugs market, by indication

 

6.5.2.2. Saudi Arabia

 

6.5.2.2.1. Saudi Arabia oncology/cancer drugs market, by drug class type

6.5.2.2.2. Saudi Arabia oncology/cancer drugs market, by indication

 

6.5.2.3. South Africa

 

6.5.2.3.1. South Africa oncology/cancer drugs market, by drug class type

6.5.2.3.2. South Africa oncology/cancer drugs market, by indication

 

6.5.2.4. Rest of LAMEA

 

6.5.2.4.1. Rest of LAMEA oncology/cancer drugs market, by drug class type

6.5.2.4.2. Rest of LAMEA oncology/cancer drugs market, by indication

 

6.5.3. Market size and forecast, by drug class type

6.5.4. Market size and forecast, by indication

 

CHAPTER 7: COMPANY PROFILES

 

7.1. AbbVie Inc.

 

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Product Portfolio

7.1.5. Business performance

7.1.6. Key strategic moves and developments

 

7.2. Astellas Pharma Inc.

 

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product Portfolio

7.2.5. Business performance

 

7.3. AstraZeneca PLC

 

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product Portfolio

7.3.5. Business performance

7.3.6. Key strategic moves and developments

 

7.4. Bristol-Myers Squibb Company

 

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product Portfolio

7.4.5. Business performance

7.4.6. Key strategic moves and developments

 

7.5. Celgene Corporation

 

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product type Portfolio

7.5.5. Business performance

 

7.6. F. HOFFMANN-LA ROCHE LTD.

 

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Product portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

 

7.7. JOHNSON & JOHNSON (Janssen Global Services, LLC,)

 

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product Portfolio

7.7.5. Business performance

 

7.8. Merck & Co., Inc.

 

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product Portfolio

7.8.5. Business performance

7.8.6. Key strategic moves and developments

 

7.9. Novartis AG

 

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product Portfolio

7.9.5. Business performance

 

7.10. Pfizer Inc.

 

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Product Portfolio

7.10.5. Business performance


List Of Figure

LIST OF FIGURES

 

FIGURE 01. ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS

FIGURE 03. TOP WINNING STRATEGIES, 2015-2018

FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 2015-2018

FIGURE 05. TOP WINNING STRATEGIES: NATURE AND TYPE, 2015-2018

FIGURE 06. TOP PLAYER POSITIONING, 2017

FIGURE 07. MODERATE BARGANING POWER OF BUYERS

FIGURE 08. HIGH BARGANING POWER OF SUPPLIERS

FIGURE 09. MODERATE THREAT OF SUBSTITUTION

FIGURE 10. MODERATE THREAT OF NEW ENTRANTS

FIGURE 11. HIGH COMPETITIVE RIVALRY

FIGURE 12. PATENTS REGISTERED/APPROVED IN THE WORLD, 2015-2018

FIGURE 13. PATENTS ANALYSIS BY YEAR, 2015 THROUGH 2018

FIGURE 14. WORLD POPULATION AGED 65 AND OVER (%)

FIGURE 15. IMPACT ANALYSES, ONCOLOGY/CANCER DRUGS MARKET

FIGURE 16. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2017 & 2025

FIGURE 17. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2017 & 2025

FIGURE 18. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR IMMUNOTHERAPY, BY COUNTRY, 2017 & 2025

FIGURE 19. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR HORMONAL THERAPY, BY COUNTRY, 2017 & 2025

FIGURE 20. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY COUNTRY, 2017 & 2025

FIGURE 21. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY, 2017 & 2025

FIGURE 22. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017 & 2025

FIGURE 23. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY COUNTRY, 2017 & 2025

FIGURE 24. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017 & 2025

FIGURE 25. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY COUNTRY, 2017 & 2025

FIGURE 26. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY COUNTRY, 2017 & 2025

FIGURE 27. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2017 & 2025

FIGURE 28. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY COUNTRY, 2017 & 2025

FIGURE 29. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY COUNTRY, 2017 & 2025

FIGURE 30. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY COUNTRY, 2017 & 2025

FIGURE 31. EUROPEAN GERIATRIC POPULATION (ABOVE 65 YEARS), 2017

FIGURE 32. ABBVIE: NET SALES, 20152017 (USD MILLION)

FIGURE 33. ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 34. ABBVIE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 35. ASTELLAS: SALES, 20152017 (USD MILLION)

FIGURE 36. ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2017 (%)

FIGURE 37. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 38. ASTRAZENECA: REVENUE, 20152017 (USD MILLION)

FIGURE 39. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 40. REVENUE, 20152017 (USD MILLION)

FIGURE 41. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 42. CELGENE: REVENUE, 20152017 (USD MILLION)

FIGURE 43. CELGENE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 44. CELGENE: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 45. ROCHE: NET SALES, 20152017 (USD MILLION)

FIGURE 46. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 47. ROCHE: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 48. J&J: REVENUE, 20152017 (USD MILLION)

FIGURE 49. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 50. J&J: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 51. MERCK: NET SALES, 20152017 (USD MILLION)

FIGURE 52. MERCK: NET SALES BY SEGMENT, 2017 (%)

FIGURE 53. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)

FIGURE 54. NET SALES, 20152017 (USD MILLION)

FIGURE 55. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 56. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 57. PFIZER: REVENUE, 20152017 (USD MILLION)

FIGURE 58. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 59. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)


List Of Table

LIST OF TABLES

 

TABLE 01. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 (USD MILLION)

TABLE 02. CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 20162023 (USD MILLION)

TABLE 03. CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 20172025 (USD MILLION)

TABLE 04. CANCER DRUGS FOR IMMUNOTHERAPY, BY REGION, 20172025 (USD MILLION)

TABLE 05. CANCER DRUGS FOR HORMONAL THERAPY, BY REGION, 20172025 (USD MILLION)

TABLE 06. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 (USD MILLION)

TABLE 07. ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 08. ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 09. ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 10. ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 11. CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 12. ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 13. ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 14. ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 15. ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 16. ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 17. ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY REGION, 20172025 (USD MILLION)

TABLE 18. ONCOLOGY/CANCER DRUGS MARKET REVENUE, BY REGION, 20172025 (USD MILLION)

TABLE 19. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 20. U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 21. U.S. CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 22. CANADA CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 23. CANADA CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 24. MEXICO CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 25. MEXICO CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 26. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 (USD MILLION)

TABLE 27. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 (USD MILLION)

TABLE 28. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 29. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 30. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 31. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 32. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 33. UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 34. UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 35. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 36. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 37. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 38. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 39. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 40. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 41. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 (USD MILLION)

TABLE 42. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 (USD MILLION)

TABLE 43. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 44. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 45. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 46. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 47. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 48. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 49. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 50. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 51. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 52. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 53. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 54. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 55. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 56. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 (USD MILLION)

TABLE 57. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 (USD MILLION)

TABLE 58. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 59. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 60. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 61. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 62. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 63. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 64. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 65. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 66. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 67. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 (USD MILLION)

TABLE 68. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 (USD MILLION)

TABLE 69. ABBVIE: COMPANY SNAPSHOT

TABLE 70. ABBVIE: OPERATING SEGMENTS

TABLE 71. ABBOTT: PRODUCT PORTFOLIO

TABLE 72. ASTELLAS: COMPANY SNAPSHOT

TABLE 73. ASTELLAS: PRODUCTS AND SERVICES

TABLE 74. ASTELLAS: PRODUCT PORTFOLIO

TABLE 75. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 76. ASTRAZENECA: OPERATING SEGMENTS

TABLE 77. ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 78. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 79. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 80. CELGENE: COMPANY SNAPSHOT

TABLE 81. CELGENE: OPERATING SEGMENTS

TABLE 82. CELGENE : PRODUCT TYPE PORTFOLIO

TABLE 83. ROCHE: COMPANY SNAPSHOT

TABLE 84. ROCHE: OPERATING SEGMENTS

TABLE 85. ROCHE: PRODUCT TYPE PORTFOLIO

TABLE 86. J&J: COMPANY SNAPSHOT

TABLE 87. J&J: OPERATING SEGMENTS

TABLE 88. J&J: PRODUCT TYPE PORTFOLIO

TABLE 89. MERCK: COMPANY SNAPSHOT

TABLE 90. MERCK: OPERATING SEGMENTS

TABLE 91. MERCK: PRODUCT PORTFOLIO

TABLE 92. NOVARTIS: COMPANY SNAPSHOT

TABLE 93. NOVARTIS: OPERATING SEGMENTS

TABLE 94. NOVARTIS: PRODUCT PORTFOLIO

TABLE 95. PFIZER: COMPANY SNAPSHOT

TABLE 96. PFIZER: OPERATING SEGMENTS

TABLE 97. PFIZER: PRODUCT PORTFOLIO

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

According to a new report published by Allied Market Research, titled,"Oncology/Cancer drugs market by Treatment Type: Global Opportunity Analysis and Industry Forecast, 2018-2025"the market was valued at USD 97,401 million in 2017, and is projected to reach USD 176,509 million by 2025, growing at a CAGR of 7.6% from 2018 to 2025.

 

Cancer is caused when the cells present in the body grow at an uncontrolled rate leading to the formation of a tumor. Cancer has different stages based on its progression. Metastasis is the final stage of the disease, which is marked by the invasion of tumor into others parts of body. The management of cancer in patients requires the use of different drugs such as hormonal therapy, immunotherapy, targeted therapy, and others.

 

The key drivers of the global oncology/cancer drugs market are surge in geriatric population and rise in collaborations & partnerships to facilitate drug development. In addition, surge in prevalence of cancer and increase in healthcare expenditure have significantly contributed toward the growth of this market. Increase in number of pipeline drugs along with high potential of emerging economies are further expected to provide lucrative opportunities for market expansion. However, adverse effects related to cancer drugs impede the market growth.

 

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

 

Regionally, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

 

Key Findings of the Oncology/Cancer drugs market:

North America occupied nearly half share of the global oncology/cancer drugs market in 2017.

The immunotherapy segment is anticipated to grow with the highest CAGR throughout the forecast period.

The breast cancer segment accounted for less than one-seventh share of the market in 2017.

Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

North America was the leading revenue contributor to the global market in 2017, garnering nearly 47.65% of the total market share, owing to high adoption rate of cancer drugs. However, Asia-Pacific is expected to grow at the highest CAGR of 9.5% from 2018 to 2025, owing to increase in disposable income; surge in research, development, & innovation activities; and rise in awareness related to different cancers.

The report provides an extensive competitive analysis and profiles of the key market players such as Amgen Inc., Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi.

 

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

 

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

READ MORE

Scope

CHAPTER 1: INTRODUCTION

 

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

 

1.3.1. List of key players profiled in the report

 

1.4. Research methodology

 

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

 

CHAPTER 2: EXECUTIVE SUMMARY

 

2.1. Key findings of the study

2.2. CXO perspective

 

CHAPTER 3: MARKET OVERVIEW

 

3.1. Market definition and scope

3.2. Key findings

 

3.2.1. Top investment pockets

3.2.2. Top winning strategies, 2017

 

3.3. Top player positioning, 2017

3.4. Porters five forces analysis

3.5. Clinical trials

3.6. Patent analysis (2015-2018)

 

3.6.1. Patent analysis, world

3.6.2. Patent analysis, by year

 

3.7. Market dynamics

 

3.7.1. Drivers

 

3.7.1.1. Rise in incidence of cancer across the globe

3.7.1.2. Surge in global geriatric population

3.7.1.3. Increase in government expenditures on healthcare

 

3.7.2. Restraints

 

3.7.2.1. Adverse effects associated with the use of cancer drugs

 

3.7.3. Opportunities

 

3.7.3.1. Untapped emerging economies

3.7.3.2. Increase in number of pipeline drugs

 

3.7.4. Impact Analyses

 

CHAPTER 4: ONCOLOGY/ CANCER DRUGS MARKET, BY DRUG CLASS TYPE

 

4.1. Overview

 

4.1.1. Market size and forecast

 

4.2. Chemotherapy

 

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market analysis, by country

 

4.3. Targeted Therapy

 

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market analysis, by country

 

4.4. Immunotherapy (Biologic Therapy)

 

4.4.1. Key market trends, growth factors, and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market analysis, by country

 

4.5. Hormonal Therapy

 

4.5.1. Key market trends, growth factors, and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market analysis, by country

 

CHAPTER 5: ONCOLOGY/ CANCER DRUGS MARKET, BY INDICATION

 

5.1. Overview

 

5.1.1. Market size and forecast

 

5.2. Lung Cancer

 

5.2.1. Market size and forecast, by region

5.2.2. Market share analysis, by country

 

5.3. Stomach Cancer

 

5.3.1. Market size and forecast, by region

5.3.2. Market analysis, by country

 

5.4. Colorectal Cancer

 

5.4.1. Market size and forecast, by region

5.4.2. Market share analysis, by country

 

5.5. Breast Cancer

 

5.5.1. Market size and forecast, by region

5.5.2. Market share analysis, by country

 

5.6. Prostate Cancer

 

5.6.1. Market size and forecast, by region

5.6.2. Market share analysis, by country

 

5.7. Liver Cancer

 

5.7.1. Market size and forecast, by region

5.7.2. Market share analysis, by country

 

5.8. Esophagus Cancer

 

5.8.1. Market size and forecast, by region

5.8.2. Market share analysis, by country

 

5.9. Cervical Cancer

 

5.9.1. Market size and forecast, by region

5.9.2. Market share analysis, by country

 

5.10. Kidney Cancer

 

5.10.1. Market size and forecast, by region

5.10.2. Market share analysis, by country

 

5.11. Bladder Cancer

 

5.11.1. Market size and forecast, by region

5.11.2. Market share analysis, by country

 

5.12. Other Cancers

 

5.12.1. Market size and forecast, by region

5.12.2. Market share analysis, by country

 

CHAPTER 6: ONCOLOGY/ CANCER DRUGS MARKET, BY REGION

 

6.1. Overview

 

6.1.1. Market size and forecast

 

6.2. North America

 

6.2.1. Key market trends, growth factors, and opportunities

6.2.2. Market size and forecast, by country

 

6.2.2.1. U.S.

 

6.2.2.1.1. U.S. oncology/cancer drugs market, by drug class type

6.2.2.1.2. U.S. oncology/cancer drugs market, by indication

 

6.2.2.2. Canada

 

6.2.2.2.1. Canada oncology/cancer drugs market, by drug class type

6.2.2.2.2. Canada oncology/cancer drugs market, by indication

 

6.2.2.3. Mexico

 

6.2.2.3.1. Mexico oncology/cancer drugs market, by drug class type

6.2.2.3.2. Mexico oncology/cancer drugs market, by indication

 

6.2.3. Market size and forecast, by drug class type

6.2.4. Market size and forecast, by indication

 

6.3. Europe

 

6.3.1. Key market trends, growth factors, and opportunities

6.3.2. Market size and forecast, by country

 

6.3.2.1. Germany

 

6.3.2.1.1. Germany oncology/cancer drugs market, by drug class type

6.3.2.1.2. Germany oncology/cancer drugs market, by indication

 

6.3.2.2. France

 

6.3.2.2.1. France oncology/cancer drugs market, by drug class type

6.3.2.2.2. France oncology/cancer drugs market, by indication

 

6.3.2.3. UK

 

6.3.2.3.1. UK oncology/cancer drugs market, by drug class type

6.3.2.3.2. UK oncology/cancer drugs market, by indication

 

6.3.2.4. Italy

 

6.3.2.4.1. Italy oncology/cancer drugs market, by drug class type

6.3.2.4.2. Italy oncology/cancer drugs market, by indication

 

6.3.2.5. Spain

 

6.3.2.5.1. Spain oncology/cancer drugs market, by drug class type

6.3.2.5.2. Spain oncology/cancer drugs market, by indication

 

6.3.2.6. Rest of Europe

 

6.3.2.6.1. Rest of Europe oncology/cancer drugs market, by drug class type

6.3.2.6.2. Rest of Europe oncology/cancer drugs market, by indication

 

6.3.3. Market size and forecast, by drug class type

6.3.4. Market size and forecast, by indication

 

6.4. Asia-Pacific

 

6.4.1. Key market trends, growth factors, and opportunities

6.4.2. Market size and forecast, by country

 

6.4.2.1. Japan

 

6.4.2.1.1. Japan oncology/cancer drugs market, by drug class type

6.4.2.1.2. Japan oncology/cancer drugs market, by indication

 

6.4.2.2. China

 

6.4.2.2.1. China oncology/cancer drugs market, by drug class type

6.4.2.2.2. China oncology/cancer drugs market, by indication

 

6.4.2.3. Australia

 

6.4.2.3.1. Australia oncology/cancer drugs market, by drug class type

6.4.2.3.2. Australia oncology/cancer drugs market, by indication

 

6.4.2.4. India

 

6.4.2.4.1. India oncology/cancer drugs market, by drug class type

6.4.2.4.2. India oncology/cancer drugs market, by indication

 

6.4.2.5. South Korea

 

6.4.2.5.1. South Korea oncology/cancer drugs market, by drug class type

6.4.2.5.2. South Korea oncology/cancer drugs market, by indication

 

6.4.2.6. Rest of Asia-Pacific

 

6.4.2.6.1. Rest of Asia-Pacific oncology/cancer drugs market, by drug class type

6.4.2.6.2. Rest of Asia-Pacific oncology/cancer drugs market, by indication

 

6.4.3. Market size and forecast, by drug class type

6.4.4. Market size and forecast, by indication

 

6.5. LAMEA

 

6.5.1. Key market trends, growth factors, and opportunities

6.5.2. Market size and forecast, by country

 

6.5.2.1. Brazil

 

6.5.2.1.1. Brazil oncology/cancer drugs market, by drug class type

6.5.2.1.2. Brazil oncology/cancer drugs market, by indication

 

6.5.2.2. Saudi Arabia

 

6.5.2.2.1. Saudi Arabia oncology/cancer drugs market, by drug class type

6.5.2.2.2. Saudi Arabia oncology/cancer drugs market, by indication

 

6.5.2.3. South Africa

 

6.5.2.3.1. South Africa oncology/cancer drugs market, by drug class type

6.5.2.3.2. South Africa oncology/cancer drugs market, by indication

 

6.5.2.4. Rest of LAMEA

 

6.5.2.4.1. Rest of LAMEA oncology/cancer drugs market, by drug class type

6.5.2.4.2. Rest of LAMEA oncology/cancer drugs market, by indication

 

6.5.3. Market size and forecast, by drug class type

6.5.4. Market size and forecast, by indication

 

CHAPTER 7: COMPANY PROFILES

 

7.1. AbbVie Inc.

 

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Product Portfolio

7.1.5. Business performance

7.1.6. Key strategic moves and developments

 

7.2. Astellas Pharma Inc.

 

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product Portfolio

7.2.5. Business performance

 

7.3. AstraZeneca PLC

 

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product Portfolio

7.3.5. Business performance

7.3.6. Key strategic moves and developments

 

7.4. Bristol-Myers Squibb Company

 

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product Portfolio

7.4.5. Business performance

7.4.6. Key strategic moves and developments

 

7.5. Celgene Corporation

 

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product type Portfolio

7.5.5. Business performance

 

7.6. F. HOFFMANN-LA ROCHE LTD.

 

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Product portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

 

7.7. JOHNSON & JOHNSON (Janssen Global Services, LLC,)

 

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product Portfolio

7.7.5. Business performance

 

7.8. Merck & Co., Inc.

 

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product Portfolio

7.8.5. Business performance

7.8.6. Key strategic moves and developments

 

7.9. Novartis AG

 

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product Portfolio

7.9.5. Business performance

 

7.10. Pfizer Inc.

 

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Product Portfolio

7.10.5. Business performance


List Of Figure

LIST OF FIGURES

 

FIGURE 01. ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS

FIGURE 03. TOP WINNING STRATEGIES, 2015-2018

FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 2015-2018

FIGURE 05. TOP WINNING STRATEGIES: NATURE AND TYPE, 2015-2018

FIGURE 06. TOP PLAYER POSITIONING, 2017

FIGURE 07. MODERATE BARGANING POWER OF BUYERS

FIGURE 08. HIGH BARGANING POWER OF SUPPLIERS

FIGURE 09. MODERATE THREAT OF SUBSTITUTION

FIGURE 10. MODERATE THREAT OF NEW ENTRANTS

FIGURE 11. HIGH COMPETITIVE RIVALRY

FIGURE 12. PATENTS REGISTERED/APPROVED IN THE WORLD, 2015-2018

FIGURE 13. PATENTS ANALYSIS BY YEAR, 2015 THROUGH 2018

FIGURE 14. WORLD POPULATION AGED 65 AND OVER (%)

FIGURE 15. IMPACT ANALYSES, ONCOLOGY/CANCER DRUGS MARKET

FIGURE 16. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2017 & 2025

FIGURE 17. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2017 & 2025

FIGURE 18. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR IMMUNOTHERAPY, BY COUNTRY, 2017 & 2025

FIGURE 19. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR HORMONAL THERAPY, BY COUNTRY, 2017 & 2025

FIGURE 20. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY COUNTRY, 2017 & 2025

FIGURE 21. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY, 2017 & 2025

FIGURE 22. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017 & 2025

FIGURE 23. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY COUNTRY, 2017 & 2025

FIGURE 24. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017 & 2025

FIGURE 25. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY COUNTRY, 2017 & 2025

FIGURE 26. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY COUNTRY, 2017 & 2025

FIGURE 27. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2017 & 2025

FIGURE 28. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY COUNTRY, 2017 & 2025

FIGURE 29. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY COUNTRY, 2017 & 2025

FIGURE 30. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY COUNTRY, 2017 & 2025

FIGURE 31. EUROPEAN GERIATRIC POPULATION (ABOVE 65 YEARS), 2017

FIGURE 32. ABBVIE: NET SALES, 20152017 (USD MILLION)

FIGURE 33. ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 34. ABBVIE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 35. ASTELLAS: SALES, 20152017 (USD MILLION)

FIGURE 36. ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2017 (%)

FIGURE 37. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 38. ASTRAZENECA: REVENUE, 20152017 (USD MILLION)

FIGURE 39. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 40. REVENUE, 20152017 (USD MILLION)

FIGURE 41. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 42. CELGENE: REVENUE, 20152017 (USD MILLION)

FIGURE 43. CELGENE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 44. CELGENE: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 45. ROCHE: NET SALES, 20152017 (USD MILLION)

FIGURE 46. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 47. ROCHE: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 48. J&J: REVENUE, 20152017 (USD MILLION)

FIGURE 49. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 50. J&J: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 51. MERCK: NET SALES, 20152017 (USD MILLION)

FIGURE 52. MERCK: NET SALES BY SEGMENT, 2017 (%)

FIGURE 53. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)

FIGURE 54. NET SALES, 20152017 (USD MILLION)

FIGURE 55. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 56. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 57. PFIZER: REVENUE, 20152017 (USD MILLION)

FIGURE 58. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 59. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)


List Of Table

LIST OF TABLES

 

TABLE 01. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 (USD MILLION)

TABLE 02. CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 20162023 (USD MILLION)

TABLE 03. CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 20172025 (USD MILLION)

TABLE 04. CANCER DRUGS FOR IMMUNOTHERAPY, BY REGION, 20172025 (USD MILLION)

TABLE 05. CANCER DRUGS FOR HORMONAL THERAPY, BY REGION, 20172025 (USD MILLION)

TABLE 06. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 (USD MILLION)

TABLE 07. ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 08. ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 09. ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 10. ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 11. CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 12. ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 13. ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 14. ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 15. ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 16. ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 17. ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY REGION, 20172025 (USD MILLION)

TABLE 18. ONCOLOGY/CANCER DRUGS MARKET REVENUE, BY REGION, 20172025 (USD MILLION)

TABLE 19. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 20. U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 21. U.S. CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 22. CANADA CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 23. CANADA CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 24. MEXICO CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 25. MEXICO CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 26. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 (USD MILLION)

TABLE 27. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 (USD MILLION)

TABLE 28. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 29. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 30. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 31. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 32. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 33. UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 34. UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 35. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 36. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 37. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 38. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 39. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 40. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 41. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 (USD MILLION)

TABLE 42. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 (USD MILLION)

TABLE 43. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 44. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 45. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 46. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 47. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 48. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 49. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 50. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 51. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 52. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 53. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 54. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 55. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 56. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 (USD MILLION)

TABLE 57. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 (USD MILLION)

TABLE 58. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 59. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 60. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 61. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 62. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 63. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 64. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 65. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 66. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 67. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 (USD MILLION)

TABLE 68. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 (USD MILLION)

TABLE 69. ABBVIE: COMPANY SNAPSHOT

TABLE 70. ABBVIE: OPERATING SEGMENTS

TABLE 71. ABBOTT: PRODUCT PORTFOLIO

TABLE 72. ASTELLAS: COMPANY SNAPSHOT

TABLE 73. ASTELLAS: PRODUCTS AND SERVICES

TABLE 74. ASTELLAS: PRODUCT PORTFOLIO

TABLE 75. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 76. ASTRAZENECA: OPERATING SEGMENTS

TABLE 77. ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 78. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 79. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 80. CELGENE: COMPANY SNAPSHOT

TABLE 81. CELGENE: OPERATING SEGMENTS

TABLE 82. CELGENE : PRODUCT TYPE PORTFOLIO

TABLE 83. ROCHE: COMPANY SNAPSHOT

TABLE 84. ROCHE: OPERATING SEGMENTS

TABLE 85. ROCHE: PRODUCT TYPE PORTFOLIO

TABLE 86. J&J: COMPANY SNAPSHOT

TABLE 87. J&J: OPERATING SEGMENTS

TABLE 88. J&J: PRODUCT TYPE PORTFOLIO

TABLE 89. MERCK: COMPANY SNAPSHOT

TABLE 90. MERCK: OPERATING SEGMENTS

TABLE 91. MERCK: PRODUCT PORTFOLIO

TABLE 92. NOVARTIS: COMPANY SNAPSHOT

TABLE 93. NOVARTIS: OPERATING SEGMENTS

TABLE 94. NOVARTIS: PRODUCT PORTFOLIO

TABLE 95. PFIZER: COMPANY SNAPSHOT

TABLE 96. PFIZER: OPERATING SEGMENTS

TABLE 97. PFIZER: PRODUCT PORTFOLIO

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS